Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Lee‘s view on the stock price

<< Previous

Bullboard Posts

Next >>

Comment by MetzGERon Feb 03, 2021 3:35pm

74 Views

Post# 32461228

RE:RE:RE:RE:RE:RE:Lee‘s view on the stock price

Yes bellend this was also my thought. There were people who wanted to sell their shares but waited for the recent volume to sell For a good price. So lee means that the actual People who bought shares are will hold them and have much higher goals

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario